Membrane-protective preparation

FIELD: chemistry.

SUBSTANCE: application of 5% water solution of sodium and potassium salts of humic acids, obtained from leonardite brown coal, in dose 10.0 mg/kg as membrane-protective preparation.

EFFECT: application of composition described above makes it possible to extend arsenal of membrane-protective preparations from low-toxic, cheap, available natural raw material.

2 dwg, 2 ex

 

The invention relates to medicine, pharmacology and pharmacy, in particular lipoic tools, and can be used for pathogenetic treatment and prevention of various diseases to protect cell membranes from the damaging effects.

Know the use of drugs with lipoic properties, in the treatment of various diseases. Used antihypoxant drug taurine (Nik), which has lipoic properties, has a positive effect on the phospholipid composition of cell membranes, improves metabolic processes in the heart, liver and other organs and tissues (Reference Vidal, http://www.vidal.ru/poisk_preparatov/dibicor~27640.htm).

Know the use of Rexona as lipoic drug in the treatment of purulent-inflammatory diseases of maxillofacial area (EN 2006110681 A, IPC A61K 38/43, A61P 43/00, 2007). Drug Rext represents the enzyme superoxide dismutase, which is an endogenous acceptor is oxygen free radicals and prevents oxidative modification of proteins, and is also associated with activation of lipid peroxidation destruction of biological cells (Handbook Vidal, http://www.vidal.ru/poisk_preparatov/rexod.htm).

Known drug oxitetraciclina succinate (Mexidol), which is an inhibitor of Svobodnoye the social processes, membraneelectrode, stabilizes the membrane structure of blood cells (red blood cells, and platelets) during hemolysis (Reference Vidal, http://www.vidal.ru/poisk_preparatov/mexidol~29603.htm). Known hepatoprotective agent for the prevention and correction of toxic liver damage, according to the description as hepatoprotector use succinate 2-ethyl-6-methyl-3-hydroxypyridine known as Mexidol. Exchange application Mexidol has lipoic effect on liver cells, toxic affected by the prolonged use of tuberculostatics (U.S. Pat. EN 2189817, IPC A61K 31/4412, A61P 43/00, 2002).

Known for the preparation of alpha-tocopherol acetate (Tocopherol), exhibiting antioxidant effect, is involved in cell proliferation, tissue respiration, and other critical processes of tissue metabolism. It is known that the tocopherol prevents increased permeability and capillary fragility, prevents hemolysis of red blood cells (Handbook Vidal, http://www.vidal.ru/poisk_preparatov/alfa-tocopherol-acetate_10321.htm). Know the use of α-tocopherol in veterinary medicine to improve hemolytic stability of erythrocytes in thermal injury of animals (Bekyarova, I. and other Protection of α-tocopherol erythrocytes from hemolysis induced thermal injury. Bulletin of experimental biology and medicine. 1989, T. 107, No. 4, S. 413-415).

Know the use for which ysenia resistance to hemolysis of erythrocytes as a natural antioxidant carnosine (β-alanyl-L-histidine) or its N-acetyl derivative in a certain range of concentrations (patent RU 2162698, IPC A61K 35/18; A61K 38/06, 2001).

Known drug Galavit (aminodimethylaniline sodium), which is an immunomodulatory drug with anti-inflammatory effect, its mechanism of action is associated with the ability to influence the functional-metabolic activity of macrophages (Reference Vidal, http://www.vidal.ru/poisk_preparatov/galavit~22901.htm). Used to increase the resistance of erythrocytes to hemolysis induced by ethanol, by introducing into the erythrocyte suspension in ethanol drug Galavit, dissolved in physiological solution (patent RU 2315605, IPC A61K 35/18, A61P 25/32, 2008).

The ability to identify isobutylphenyl to protect the membrane of erythrocytes from oxidative stress, defined in terms of spontaneous and induced by hydrogen peroxide hemolysis of erythrocytes (Lipoic properties isobutylphenyl - a new class of antioxidants / Shevchenko O. G. [and others] // Biological membranes: a journal of membrane and cell biology, 2013. - So 30, No. 1. - S. 40.)

As a means with gepatoprotektoram action used ascorbate lithium with gepatoprotectornoe activity against the hemolysis of erythrocytes under the influence of alcohol and different lower toxicity compared to other drugs lithium (U.S. Pat. EN 2351326 C2, IPC A61K 31/375, A61P 43/00, A61P 39/00, 2009).

The task of nastoyascheevremya is expanding Arsenal of known lipoic funds for protection of biological membranes at various damaging effects.

The technical result consists in the use of the drug containing salts of humic acids, which are obtained from low-toxic, cheap, available natural raw materials.

The technical result is achieved by the fact that as lipoic tools use an aqueous solution of the sodium and potassium salts of humic acid derived from brown coal leonardite at a dose of 10.0 mg/kg

Conditional title of the proposed lipoic tools - HUMATE of leonardite. Substance powder is produced by LLC "HUMATE", , Irkutsk, name and designation of the products: "HUMATE" is a fertilizer based on humic acids for agricultural use, THE 2189-004-41764643-98. It lipoic properties are not known.

For production of the proposed lipoic tools - aqueous solution of the sodium and potassium salts of humic acids leonardite - use relatively cheap substance, which is obtained industrially available raw materials in large volumes in an environmentally safe manner (Perminova I. C. Humic substances - a challenge to the chemists of the XXI century / I. C. Perminova // Chemistry and life, 2008. No. 1. - 50 C.-55).

The proposed substance of HUMATE of leonardite belongs to the class of natural compounds, called humic substances. Humic substances and salts of humic acids (humates) have RA is nenapravlenie biological activity, in recent years, increasingly discusses the possibility of their application in medicine and pharmacy (Dry A. S. prospects of application of humic and humanophobia acids in medicine and pharmacy / A. C. Dry, P. C. Kuznetsov // Medicine in Kuzbass. - 2009. No. 1. - S. 10-14.). Features of the chemical structure of humic substances cause their surface-active properties (On the mechanism antidote action of humates in relation to the oil / A. C. Daurov [and other] // bull. WSNS WITH THE RAMS. - 2005. No. 6 - N-143-146; a Shrub D. I. Combined effect of petroleum products and "HUMATE" on Daphnia / A. I. Shrub, A. C. Daurov // Siberian ecological journal. - 2004. No. 1. - 35 C.-40), which leads to the ability to solubilisate and dispersing hydrophobic organic matter, increasing their solubility and increasing the hydrophilicity of the surfaces of cells (Possible mechanisms of biological action of humic substances / Shrub D. I. [and other] // Siberian journal of medicine. - 2008. No. 6. - S. 76-79). This feature of humic substances suggests the possibility of their influence on the properties of lipoproteins and other components of biological membranes.

Known application of humic substances and containing natural substrates, in different branches of medicine. For example, it is known the use of oxidate peat as a means for the treatment of patients with HRO is practical dermatoses (U.S. Pat. EN 2187315 C2, IPC A61K 35/10, A61P 37/04, 2002); use of products containing sodium HUMATE from wood-grass peat deposits "Dark" Tomsk region as a means of having antimicrobial and antifungal activity (U.S. Pat. EN 2340328 C1 IPC A61K 9/06; A61K 35/10; A61P 31/10, 2008); the use of humic acids and humates as biologically active additives in the cosmetic industry with antioxidant activity (U.S. Pat. EN 2094042 C1 IPC A61K 7/00, A61K 7/40, 1997); for care of hair and scalp on the basis of humic concentrate, which is a product of peat processing solution of sodium hydroxide or potassium when activated oxygen in the process of ozonation and subsequent neutralization with a solution of citric or acetic acid, containing the dry substance of humic acids not less than 2.8 wt.% (U.S. Pat. EN 2394556 C1 IPC A61K 8/97, A61Q 5/12, 2010); a method of treating gastric ulcer and duodenal ulcer by using medicines, obtained by processing of peat (U.S. Pat. EN 2357741 C1 IPC A61K 35/10; A61P 1/04, 2009).

In Fig.table 1 presents the results of determination of acute toxicity of HUMATE of leonardite after a single oral administration; Fig.2 presents curves of hemolysis in the test sample and under the influence of HUMATE of leonardite.

Example 1.

The study of acute toxicos and aqueous solution of sodium and potassium salts of humic acids, derived from brown coal (hereinafter referred to as the HUMATE of leonardite), the oral method of administration held on 30 white outbred mice-males weighing 22,0±5,3 g, divided into groups of 10 goals to 3 of the studied doses. HUMATE of leonardite was introduced in the form of a 5.0% aqueous solution once orally via gastric metal probe. Used doses which exceed the maximum therapeutic (10 mg/kg) 25 times (dose of 250.0 mg/kg, which corresponds to a volume of 0.1 ml per 20 g of body weight of a mouse), 50 times (dose of 500.0 mg/kg, a volume of 0.2 ml/20 g) and 100 times (dose 1000,0 mg/kg, volume of 0.4 ml/20 g).

Revealed that none of the studied doses (250.0 mg/kg, 500.0 mg/kg, 1000,0 mg/kg) found no deaths during the follow-up for the first night and over the next 14 days. There were no changes in behavioral responses (not identified increased excitability, nervousness, aggression, fearfulness), revealed no changes in neuromuscular excitability (tremors, convulsions, ataxia, changes in reflexes provisions changes reactions to touch, change the tone of the skeletal muscles). There has been no changes on the part of the autonomic innervation, because there were no changes in salivation, therasense coat; not identified changes in food and water consumption (from 1.4 to 3.2 ml per head per day) in experimental animals (Fig.). Enter oral dose greater than 1000 mg/kg does not seem technically feasible and impractical, because studied the maximum dose of 1000 mg/kg can be attributed HUMATE of leonardite to non-lethal compounds (moderately hazardous substances - median lethal dose LD50when the stomach is in the range 151-5000 mg/kg - III class of hazard) and makes possible its use as lipoic tools.

Thus, in accordance with GOST 12.1.007-76 HUMATE of leonardite is non-lethal and can be attributed to the III class of hazard (moderately hazardous substances - LD50when introduced into the stomach 151-5000 mg/kg).

Example 2.

As lipoic funds from natural raw materials, ensuring the protection of biological membranes with damaging effects, used an aqueous solution of the sodium and potassium salts of humic acid derived from brown coal (HUMATE of leonardite).

To study lipoic properties of HUMATE leonardite used the modified method of registration of chemical (acid) erythrogram on Terskov I. A., Gitelson I. I. (1957), allowing to assess structural and functional properties and the permeability of biological membranes (Gitelson I. I. Erythrogramma as a method of clinical studies of blood / I. I. Gitelson, I. A. Terskov. - Krasnoyars is: Publishing house of the Siberian branch of the USSR Academy of Sciences, 1959. - 247 S.; Terskov I. Method A. chemical (acid) erythrogram // I. A. Terskov, I. I. Gitelson // Biophysics. - 1957. - So 11, Vol.2. - S. 259-266; Workshop on Biophysics / Century, Artyukhov [and other] / edited Century, Artyukhova). - Voronezh: Publishing house of Voronezh state University, 2001. - S. 147-161). Cumulative to date actual data suggest that erythrocytes are involved in the pathological process not only with hematological diseases, but also undergo major changes in the structure and function in diseases of different Genesis. The choice of erythrocyte membranes as the object of study is dictated by the fact that it has common principles of molecular structure of plasma membranes. Therefore, the patterns of changes in the structure and function of the erythrocyte membrane with a certain degree of correction can be extrapolated to other membrane systems. In addition, the simplicity of the organization of the erythrocyte gives the opportunity to study the functional properties of the plasma membrane without interference imposed intracellular membrane structures and organelles (Molecular disrupt the membrane of red blood cells in the pathology of different Genesis are typical reaction: the contours of the problem / Novitskiy centuries [and other] // Bulletin of Siberian medicine, 2006. No. 2. - S. 62-69; Postnov Y. C. Primary hypertension as pathology of cell membranes / Y. C. Postnov, S. N. Orlov. - M.:Medicine, 1987. - 192 S.).

To study lipoic properties of HUMATE leonardite used the model of acid hemolysis of erythrocytes induced by hydrochloric acid. Estimated lipoic properties of an aqueous solution of HUMATE of leonardite at a dose of 10.0 mg/kg pre-incubated with a suspension of erythrocytes at 37°C for 40 min incubation Temperature of 37°C is selected as corresponding to the temperature of the human body, incubation duration 40 min is chosen as the average time required for admission introduction of medicinal substances in the blood plasma. The concentration of HUMATE leonardite, equivalent to a dose of 10.0 mg/kg, chosen experimentally based on the results of a series of preliminary experiments with doses of 1.0 to 5.0, and 10.0 and 20.0 mg/kg of incubation. Analysis of erythrogram was carried out by graphical and mathematical way. Expected constant maximum rate of hemolysis (Kmax, Rel. unit) is a parameter that characterizes the proportion of red blood cells simultaneously entered into the stage of hemolysis; determined the relative amount of hemolyzed cells (G, %) at different points in time monitoring, indicators of structural state of erythrocyte membranes when hemolysis was assessed by the estimated parameters in accordance with the methodology (Workshop on Biophysics / Century, Artyukhov [and other] / [edited Century, Artyukh the VA]. - Voronezh: Publishing house of Voronezh state University, 2001. - S. 147-161).

The HUMATE solution of leonardite at a dose of 10.0 mg/kg was added directly to the working suspension of red blood cells, after which the mixture of red and HUMATE of leonardite were subjected to pre-incubation in an incubator at 37°C for 40 minutes the Experiments were carried out in 3 series of experiments, the obtained results were subjected to statistical analysis with calculation of average values. In each series of experiments studies were performed in parallel samples, one of which was the control (erythrocytes and hemolytic) and the second experimental (red blood cells, HUMATE solution of leonardite, hemolytic).

It is established that the kinetic curve of the process of hemolysis in the test sample corresponds to the standard and is characterized by an S-shaped form. The offset of the S-shaped curve in the first few minutes below the zero line connected with ferulacea erythrocytes. Then the process of hemolysis slowly grows in its initial part and further ascending part of the kinetic curve of hemolysis reflects the destruction of the least sustainable of erythrocytes. Then curve sharply rises in the range from 2 to 5 minutes, describing the entry into the process of hemolysis main mass of red - registered phase own hemolysis. The period of plateau reflects the destruction of the most persistent erytrocyte is. The process ends by an average of 7 minutes with a total percentage of hemolysed cells (G, %) average 84,99±4,810%. Thus the estimated value of the constant maximum speed of hemolysis (Kmax) was 7,115±0,830 Rel. units (Fig.2).

HUMATE of leonardite at a dose of 10.0 mg/kg provided significant significant decrease in Kmax63.4%, indicating a decrease in the rate of hemolysis and the decrease in intensity of the process of destruction of cells. HUMATE of leonardite significantly reduced the percentage of collapsed cells during the observation period (Fig.2) 270 sec process revealed a reduction in the number of hemolyzed erythrocytes on 29,26%, 375 sec respectively 32,63% and by the end of the process of hemolysis on 735 s - a decrease in the total number of damaged cells in 20,45%, which was significantly lower compared with control. Analysis of the shape of the curve of hemolysis (Fig.2) clearly showed that despite the presence in the environment of HUMATE leonardite dynamics of the process of acid hemolysis of erythrocytes varies curve is shifted to the right and becomes more gentle, which should be interpreted as the rise time and the degree of stability of erythrocytes by srednestan and highly resistant populations to damaging action of acid hemolytica. This effect indicates an increase in resistance of memb the Academy of Sciences of cells to the action of damaging factors and linked to the ability of HUMATE of leonardite to induce conformational structural-functional changes of cell membranes, due to the interaction with lipoproteinemia components, resulting in reduced permeability to ions, providing increased osmotic resistance of the membrane.

Thus, for the first time revealed the ability of the HUMATE solution of leonardite at a dose of 10.0 mg/kg (with incubation at 37°C for 40 min) to normalize the permeability of cell membranes, as evidenced by the decrease in the rate of destruction of cells under the action of acid hemolytica and a decrease in the number of destroyed cells and indicates the presence of lipoic activity of HUMATE leonardite.

The use of a 5% aqueous solution of sodium and potassium salts of humic acids obtained from brown coal leonardite, at a dose of 10.0 mg/kg as lipoic funds.



 

Same patents:

FIELD: pharmacology.

SUBSTANCE: agent possessing detoxification activity, containing succinic acid, 10% ethanol extract of propolis, polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 4000, Cremophor CO-40, Tween-80 and purified water in certain proportions.

EFFECT: agent possesses the detoxification action, the uniform release of the active substances and the pronounced prolonged action.

2 cl, 4 dwg, 4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to radiation and experimental biology, biotechnology and medicine, namely to means of radiological protection and to stimulators of colony formation of stem cells. Invention can be used in research and clinical practice for protection of living organisms in case of exposure to ionising radiation, in emergency and military medicine, in case of emergency situations as means for protection against radiation injury. Claimed is application of preparation gamma-plant as radioprotector with colony-stimulating properties for increasing survival and improving state of organisms, subjected to irradiation. Gamma-plant is non-toxic polysaccharide of vegetable origin, registered by Ministry of Health of the Russian Federation and allowed for medical application; Gamma-plant is included into Russian Pharmacopoeia in section FG-9 "non-narcotic analgesics".

EFFECT: invention makes it possible to increase efficiency of colony formation of stem cells in spleen 2,0-2,3 times, increases survival of experimental animals to 95% with coefficient of dose reduction factor DRF, equal 2-2,2.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: medicine.

SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.

EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulatory composition for injection into a mammal. The immunomodulatory composition for injection into a mammal containing a hydrolysate prepared by acid and/or enzymatic hydrolysis of one or more bioresources specified in a group consisting of bivalve molluscs, annelids, leeches, and water taken in certain proportions. A method for preparing the immunomodulatory composition for injection into a mammal. A method of treating a pathological condition in a mammal in need thereof involving the injections of the immunomodulatory composition into the above mammal. Using the composition for normalising metabolism into the mammal in need thereof.

EFFECT: composition enables extending the range of products with immunomodulatory activity for injections.

19 cl, 7 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

EFFECT: improvement of efficiency of the method.

FIELD: medicine.

SUBSTANCE: group of inventions relates to veterinary and medicine, in particular to obtaining and application of biopreparations for immunotherapy of ecopathologies. The group of inventions includes obtaining a protein antigen from a mixture of anatoxins from three enteropathogenic virulent strains of a pathogen of escherichiosis of calves E.coli No. 378, 379, 380 by their growing on Hottinger medium with further addition of 0.4-0.5% formalin, following thermostating for 10-12 days and cooling the mixture of anatoxins with a sterile solution of aluminium hydroxide, after that obtaining radioantigen from E.coli "PL-6" by growing cultures on a meat infusion agar with further washing away a biomass by a physiological solution and irradiation of the obtained suspension with a concentration of 1.2·1010 m.c./cm3 on a gamma-installation in a dose of 140-150 Gr with following thermostating and extraction of radiotoxin with 70% acidified with 0.05% hydrochloric acid to pH 5.5 ethanol, following evaporation of the exractant to the initial volume, after that, obtaining protein-cadmium radioantigen first by preliminary dechlorination of cadmium chloride, obtaining cadmium hydroxide, addition into the obtained 2.7% solution of the antigen of 0.77% solution of cadmium hydroxide in a ratio of 1:1 with following thermostating at a temperature of 37°C for 30 minutes, evaporation and dissolution of the residue to 12.8% concentration, further obtaining protein-cadmium radioantigen by an addition of 1.2% solution of a mixture of three anatoxins of E.coli and 12.8% solution of cadmium radioantigen in a ratio of 1:9, conjugation of components at room temperature for 8-10 hours, standardisation by a dry substance to 10% concentration and pouring into vials, and storage at a temperature of 4-6°C. The group of inventions also relates to a method of treating radiation, chemical and/or bacteriological damage to an organism by introduction of 10% solution of complex protein-cadmium radioantigen.

EFFECT: application of the group of inventions is effective in treatment of radiation, chemical and/or biological damage.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and veterinary science and aims at increasing the radioresistance in mammals. In the period of 12 hours to 20-30 minutes before a radiation exposure and immediately thereafter, 0.11% oil preparation of chlorophyll is introduced into the mammals. Linseed oil is used as an oil base. The preparation is introduced in a dose of 11-12 mg/kg intramuscularly.

EFFECT: method enables increasing the radioresistance and survival rate in the mammals.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: composition for treating oxidative stress comprises ball-shaped lipoic acid or one of salts thereof, and at least one lipophilic medium. The lipoic acid balls represent particles consisting of an inert core (a nucleus) coated with lipoic acid which is coated with a first layer of an isolating polymer, and with a second polymer layer resistant (stable) at gastric pH. What is also described is a preparation for treating oxidative stress with an unified dose containing the above composition. The preparation is presented in the form of a soft gelatin capsule.

EFFECT: compositions according to the invention are stable in the lipophilic medium.

22 cl, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the field of medicine, namely to pharmacology, and describes a composition, containing fulvic acid or its salt and an antifungal compound, selected from fluconazole and amphotericin B. In accordance with the first version of the implementation the composition contains about 10 ml/kg of a solution of from about 0.25% to about 1% (wt/vol) fulvic acid or its salt and of about 10 mg/kg fluconazole. In accordance with the second version of the implementation the composition contains 0.25% (wt/vol) of the solution of fulvic acid or its salt and from about 0.06 mg/l to about 0.5 mg/l of amphotericin B.

EFFECT: invention can be used in a method of treating a fungal infection of the human or animal body, the method includes the introduction to an object, requiring it, of a therapeutically effective quantity of the composition.

11 cl, 1 dwg, 10 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: method of obtaining a sapropel concentrate includes the extraction of easily separable water-soluble components of a native sapropel by the centrifugation and separation of a supernatant, with the supernatant being discharged into a vacuum evaporating aggregate, in which the concentration of the claimed supernatant is realised by the evaporation in vacuum, and the sapropel sediment is placed in a drying chamber, separated from the vacuum chamber with a net and a hermetic lock, heated with the simultaneous creation of a vacuum in the vacuum chamber, after which the sapropel sediment is subjected to a vacuum-impulse influence, the remaining moisture separated from the sediment is pumped by a vacuum pump into the vacuum evaporating aggregate, where it is condensed and concentrated at the same modes as the supernatant, after that, the dry sediment (extraction cake) is milled and packed, and the obtained concentrate is poured into vessels and each of the obtained target products is applied by purpose or the solubilisation of the milled dry sediment (extraction cake) is realised in the obtained concentrate of easily separable water-soluble components under certain conditions.

EFFECT: method makes it possible to preserve all useful substances of the native sapropel.

1 dwg

FIELD: chemistry.

SUBSTANCE: peat in a mixture with water is loaded into a dispersion chamber, then the dispersion chamber is pressurised, static pressure of 5-7 atm is supplied into it and the content of the chamber is processed by ultrasonic vibrations with a density of insonification not less than 50 W/cm2, providing the sound pressure on the mixture of peat with water for the preliminarily specified time, which exceeds the static pressure by 2-3 times. The invention also relates to biogel, obtained by the claimed method.

EFFECT: obtaining water-peat biogel with nanosized particles, in which useful substances do not lose their efficiency.

4 cl

FIELD: medicine.

SUBSTANCE: method for preparing an agent showing anti-inflammatory action involves an alkali treatment of terrestrial peat and extraction in the alcohol-chloroform mixture. The terrestrial peat preliminarily ground and dried is milled in the AGO planetary activator before the extraction in the presence of solid alkali and sodium percarbonate for 1 min.

EFFECT: method enables higher antioxidant and anti-inflammatory activity of the terrestrial peat agent by increasing a yield of the extractive biologically active substances.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a medicated mud composition. The medicated mud composition contains prepared sludge argillaceous deposits of Tambukan Lake, Witepsol W 35, Witepsol H 15, polyethylene glycol 1500, Cremophore RH, as well as carbon-dioxide herbal extracts specified in a group consisting of at least the common willow, sea buckthorn, oak, calendula, licorice, brier, sage and/or carbon-dioxide extract of propolis taken in certain relations.

EFFECT: composition enables extending the range of medicinal agents using therapeutic sludge argillaceous deposits.

10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a treating-preventive mud composition. The treating-preventive mud composition contains preliminarily prepared silt-clayey deposits of lake Tambukan, polyethyleneglycol 4000, polyethyleneglycol 1500, cremophor RH, as well as a carbon dioxide extract of propolis and/or a carbon dioxide vegetable extract, selected from the group, which includes, at least, eucalyptus, dog-rose, hop, laurel, chamomile, licorice and oak, taken in a specified ratio of components.

EFFECT: composition has an increased treating-preventive activity with respect to a patient's organism.

9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely paediatrics and can be used for treating community-acquired pneumonia in children. That is ensured by prescribing an electrophoresis with an aqueous solution of the natural preparation Relikt-05 on the second day after temperature normalisation with a daily bipolar application of electrodes on the chest at current intensity 2 to 4-5 mA in children aged 3-7 years old and at 5 to 8 mA in children aged 7 and older with underlying drug therapy. The procedure length makes 10 to 15 minutes daily; the therapeutic course is 6-7 procedures.

EFFECT: method enables improving outcome of the integrated therapy in children suffering community-acquired pneumonia by faster resolution of infiltration centres in pulmonary tissue, increasing a neutrophil phagocytic rate and the content of active microelements, activating the endogenous antioxidant and antiradical protection with no complications.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention represents a protective coating for removable dentures differing by the fact that the coating is presented by an alcoholic amber varnish.

EFFECT: invention provides preparing a strong and stable coating for dentures possessing an ability to inhibit growth and development of microorganisms, formation of dental plaque in the form of a biofilm.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynaecology, reflexotherapy and pelotherapy. A method includes carrying out a course of antibacterial and/or antiviral therapy, which is started on 5-7 day of a menstrual cycle. From 5-7 day of the following menstrual cycle a course of pharmacopuncture is performed by introduction of homeopathic preparations into acupuncture points (AP). On 1, 3, 5, 7, 9, 11 and 13 days of the course Traumel C is introduced into points E36 (2), V31 (2), V32 (2), V33 (2), V34 (2). On 2, 4, 6, 8, 10, 12, 14 days of the course Ovarium compositum is introduced in AP Rp6 (2). Simultaneously with the course of pharmacopuncture or starting from 5-7 day of the following menstrual cycle a course of pelotherapy is carried out. Introduction of gel, based on the Dead Sea mud, is performed rectally for 30 minutes, 1 time per day.

EFFECT: method ensures recovery of the two-phase menstrual cycle due to normalisation of endometrium and vagina biocenosis, improvement of local immune and vegetative status, increases duration of remission.

4 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a method for preparing the therapeutic mud. The method for preparing the therapeutic mud consists in filling sapropel with sodium hydroxide, heating, cooling and diluting with water, settling, siphonage and filtering; the filtrate is poured into an anode chamber of an electrolytic cell, electrodes of which are made from fine schungite placed into a fine porous non-metallic envelope with a schungite or graphite rod; the rods are attached to the output terminals of a power source; the filtrate electrolysis involves ultrasonic oscillation generation; the filtrate electrolysis is terminated when a target humic concentrate is formed on the surface of the anode and anode chamber; the target concentrate is removed from the surface of the anode and anode chamber and is used as the therapeutic mud.

EFFECT: method described above enables preparing the mud with more pronounced therapeutic and stimulating properties that enables extending the range of using the prepared mud.

FIELD: medicine, phthisiology.

SUBSTANCE: in early period the preparation "Yantar-antitoks" is used in the dose 0.5 g, 3 times per a day for one month in addition to the conventional antituberculosis therapy. Invention promotes to elimination of symptoms associated with the total intoxication, resorption of focus-infiltration changes, elimination of destructions and ceasing secretion of microorganisms for shorter periods. Invention can be used in treatment of pulmonary tuberculosis.

EFFECT: improved method for treatment.

4 tbl, 1 ex

Up!